Inhaled, dry powder insulin

U.S. Pharmacist

Volumn 32, Issue 10, 2007, Pages 3-8

  Neumiller, Joshua J ^a   Mai, Yvonne L ^a   Setter, Stephen M ^a   Iltz, Jason L ^a,b   Campbell, R Keith ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Integrated Health Professionals   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; METFORMIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; SULFONYLUREA;

CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STORAGE; DRY POWDER; DYSPNEA; EPISTAXIS; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; SPIROMETRY; SPUTUM;

EID: 47749084300     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (23)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2005.
2. World Health Organization: Diabetes: What is Diabetes? Available at: http:www.who.int/mediacentre/factsheets/fs312/en/. Accessed July 25, 2007.
3. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. Adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
6. Cefalu WT. Evaluation of alternative strategies for optimizing glycemia; progress to date. Am J Med. 2002;113(6A): 23S-35S.
7. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-428.
8. Quattrin T, Belanger A, Bohannon NJV, et al., for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared to subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2622-2627.
9. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331-335.
10. Skyler JS, Weinstock RS, Raskin P, et al., for the Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care. 2005;28:1630-1635.
11. Norwood P, Dumas R, Cefalu W, et al. Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (Exubera). J Clin Endocrinol Metab. 2007;92(S6):2211-2214.
12. Skyler JS, Jovanovic L, Klioze S, et al., for the Inhaled Human Insulin Type 1 Diabetes Study Group. Two year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care. 2007;30:579-585.
13. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care. 2005;28:1922-1928.
14. Weiss SR, Cheng SL, Kourides IA, et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med. 2003;163:2277-2282.
15. Simonson DC, Turner RR, Hayes JF, et al. Improving quality of life in type 2 diabetes when Exubera is added after failure on metformin: a multicenter, international trial [abstract]. Diabetologia. 2004;47(suppl 1):A311.
16. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open-randomized, parallel-group study to compare the efficacy and safety profile inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care. 2006;29:1282-1287.
17. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005;143:549-558.
18. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356-2362.
19. Cefalu WT, Skyler JS, Kourides IA, et al., for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 2001;134:203-207.
20. Rosenstock J, Foyt H, Klioze S, et al. Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM) [abstract]. Diabetes. 2006;55(suppl):abstract 109-OR.
21. Exubera [US package insert]. Pfizer Inc. Exubera (insulin human [rDNA origin]) inhalation powder: New York, NY: Pfizer Labs; 2007.
22. Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal-bolus insulin regimen in type 1 diabetic subjects. Diabetes Care. 2004;28:1630-1635.
23. Setter SM, Levien TL, Iltz JL, et al. Inhaled dry powder insulin for the treatment of diabetes mellitus. Clin Ther. 2007;29:795-813.